Home/Pipeline/OV882

OV882

Angelman Syndrome

PreclinicalIND-enabling studies

Key Facts

Indication

Angelman Syndrome

Phase

Preclinical

Status

IND-enabling studies

Company

Ovid Therapeutics

About Ovid Therapeutics

Ovid Therapeutics is a clinical-stage biopharmaceutical company with a mission to transform the lives of patients with rare neurological disorders. The company leverages its expertise in brain biology to develop targeted therapies for conditions like Angelman syndrome, CDKL5 deficiency disorder, and developmental and epileptic encephalopathies. Ovid's strategy involves both internal development and strategic partnerships to advance its pipeline. The company is publicly traded and has established collaborations with leading research institutions and biotech partners.

View full company profile

Therapeutic Areas

Rare Neurological Diseases Epilepsy Neurodevelopmental Disorders

Other Angelman Syndrome Drugs

Drug	Company	Phase	Status
GTX-102	Ultragenyx Pharmaceutical	Phase 1/2	Active
NNZ-2591	Neuren Pharmaceuticals	Phase 2	Active